Eighth edition staging of thoracic malignancies: Implications for the reporting pathologist

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Context.-The Staging and Prognostic Factors Committee of the International Association for the Study of Lung Cancer, in conjunction with the International Mesothelioma Interest Group, the International Thymic Malignancy Interest Group, and the Worldwide Esophageal Cancer Collaboration, developed proposals for the 8th edition of their respective tumor, node, metastasis (TNM) staging classification systems. Objective.-To review these changes and discuss issues for the reporting pathologist. Data Sources.-Proposals were based on international databases of lung (N=94 708), with an external validation using the US National Cancer Database; mesothelioma (N = 3519); thymic epithelial tumors (10 808); and epithelial cancers of the esophagus and esophagogastric junction (N = 22 654). Conclusions.-These proposals have been mostly accepted by the Union for International Cancer Control and the American Joint Committee on Cancer and incorporated into their respective staging manuals (2017). The Union for International Cancer Control recommended implementation beginning in January 2017; however, the American Joint Committee on Cancer has deferred deployment of the eighth TNM until January 1, 2018, to ensure appropriate infrastructure for data collection. This manuscript summarizes the updated staging of thoracic malignancies, specifically highlighting changes from the 7th edition that are relevant to pathologic staging. Histopathologists should become familiar with, and start to incorporate, the 8th edition staging in their daily reporting of thoracic cancers henceforth.

    Fingerprint

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Members of the International Association for the Study of Lung Cancer Staging and Prognostic Factors and Pathology Committees (2018). Eighth edition staging of thoracic malignancies: Implications for the reporting pathologist. Archives of Pathology and Laboratory Medicine, 142(5), 645-661. https://doi.org/10.5858/arpa.2017-0245-RA